David J. King

High-Level Expression of a Recombinant Antibody from Myeloma Cells Using a Glutamine Synthetase Gene as an Amplifiable Selectable Marker

C. R. Bebbington, G. Renner, Scott Thomson et al. · Nature Biotechnology · 1992 · 465 citations

Pharmacy, Molecular Biology, Antibody Engineering +16

A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody

Sarojani Angal, David J. King, Mark Bodmer et al. · Molecular Immunology · 1993 · 243 citations

Pharmacy, Biochemistry, Molecular Biology +13

Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells.

Oliver W. Press, Darning Shan, J Howell-Clark et al. · PubMed · 1996 · 212 citations

Medicine, Nuclear Medicine, Oncology +13

Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3

Dominique Desplancq, David J. King, Alastair D. G. Lawson et al. · Protein Engineering Design and Selection · 1994 · 122 citations

Pharmacy, Immunology, Molecular Biology +14

Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans.

M.B. Khazaeli, Mansoor N. Saleh, T.-P. Liu et al. · PubMed · 1991 · 120 citations

Pharmacy, Pharmacokinetics, Pharmacology +17